Jardiance Cost in Iowa 2026: Prices, Insurance, Medicaid, and Compounded Options

What Does Jardiance Actually Cost in Iowa in 2026?

Without insurance, Jardiance costs approximately $680 per month at Iowa retail pharmacies in 2026, matching the Boehringer Ingelheim and Eli Lilly manufacturer list price. That figure applies whether you fill at a Hy-Vee pharmacy in Des Moines or a small independent pharmacy in Sioux City. Cash-pay prices rarely drop below $620 even with a GoodRx coupon at in-state chains [1].

The drug is available as 10 mg and 25 mg oral tablets taken once daily. For type 2 diabetes management, physicians typically start at 10 mg, increasing to 25 mg if additional glycemic lowering is needed and the patient tolerates the lower dose. For heart failure with reduced ejection fraction, the 10 mg dose is the FDA-approved therapeutic target and increasing to 25 mg adds no additional cardiovascular benefit per the EMPEROR-Reduced trial (N=3,730), which showed a 25% relative reduction in the primary composite of cardiovascular death or hospitalization for heart failure [2].

Empagliflozin belongs to the SGLT2 inhibitor class. Its mechanism involves blocking the sodium-glucose cotransporter 2 in the proximal tubule of the kidney, causing roughly 70 grams of glucose to be excreted in urine per day [3]. That same renal mechanism drives natriuresis, which reduces preload and afterload, explaining much of the cardiovascular benefit seen in outcome trials.

GoodRx coupons at major Iowa chains (Walgreens, CVS, Hy-Vee) typically show a discounted cash price between $620 and $660. That is a modest reduction from list, not a transformation of affordability. Patients paying out of pocket should exhaust every manufacturer and assistance program before defaulting to full cash price.

Does Iowa Medicaid Cover Jardiance?

Iowa Medicaid does not cover Jardiance (empagliflozin) for the vast majority of members as of 2026. The Iowa Department of Health and Human Services Preferred Drug List places SGLT2 inhibitors in a non-preferred or excluded tier for most Medicaid managed care plans in the state [4].

This absence is a significant gap in care. The American Diabetes Association's 2024 Standards of Care recommend SGLT2 inhibitors as preferred add-on agents in patients with type 2 diabetes and established cardiovascular disease, heart failure, or CKD, regardless of baseline HbA1c [5]. When Medicaid does not cover the preferred agent, physicians and patients are pushed toward older, less cardioprotective drugs.

A prior authorization (PA) request is theoretically possible for Iowa Medicaid members with documented heart failure or CKD, but approval rates are low and the documentation burden is high. Patients facing a PA denial should work with their prescribing clinician to submit an appeal citing the ADA Standards of Care and the EMPA-REG OUTCOME trial data, which showed a 38% relative reduction in cardiovascular death compared with placebo in patients with type 2 diabetes and established cardiovascular disease (N=7,020, P<0.001) [1].

Iowa Health Link, the managed Medicaid program, contracts with AmeriHealth Caritas Iowa, Iowa Total Care, and Molina Healthcare of Iowa. Each plan maintains its own formulary, and none of these three plans listed empagliflozin as a preferred tier agent as of the 2026 formulary year. Patients should check their specific plan's drug lookup tool annually, as formularies can change January 1.

Which Insurance Plans Cover Jardiance in Iowa?

Most large commercial plans operating in Iowa do cover Jardiance, usually on tier 2 or tier 3 of the formulary. Tier 2 typically means a $30, $60 copay per month. Tier 3 can run $80, $150 per month before the savings card applies [6].

Major Iowa commercial insurers and their typical Jardiance placement include the following. Wellmark Blue Cross Blue Shield of Iowa lists Jardiance on tier 2 for most commercial group plans, yielding a copay of roughly $35, $55 per month. United Healthcare and Aetna plans available through Iowa employers generally place Jardiance on tier 3, where the savings card is most useful. Principal Financial Group, headquartered in Des Moines and a major employer insurance carrier in Iowa, follows a similar tier-3 pattern for specialty cardiovascular-metabolic drugs.

Medicare Part D is separate from commercial insurance. CMS does not consider SGLT2 inhibitors "protected class" drugs, so Part D plan formularies vary widely. Iowa Medicare beneficiaries should use the Medicare Plan Finder at medicare.gov each October to compare specific plans by Jardiance tier and cost-sharing. In 2026, the Medicare Part D annual out-of-pocket cap of $2,000 (established by the Inflation Reduction Act) may meaningfully reduce costs for patients who previously reached catastrophic coverage [7].

How Does the Boehringer Ingelheim / Lilly Savings Card Work in Iowa?

The Jardiance savings card, co-sponsored by Boehringer Ingelheim and Eli Lilly, is available to commercially insured patients across Iowa and can reduce monthly cost-sharing to as little as $10 per month [8].

Eligibility rules are specific. The card is only valid for patients with commercial (private) insurance. Medicare, Medicaid, and other government-funded insurance programs are explicitly excluded. There is no income test for the savings card itself. Patients enroll at jardiance.com or by calling the program line, and the card is applied at the pharmacy like a secondary insurance coupon.

The program caps annual savings at a fixed dollar amount that Boehringer Ingelheim adjusts periodically, so patients should verify the current cap each January. In prior program years, the annual maximum benefit was $3,600, meaning patients who hit that ceiling in high-copay plans reverted to full tier cost-sharing for the remainder of the calendar year.

Pharmacists at Iowa retail chains are generally familiar with the Jardiance savings card. If a pharmacy counter staff member indicates the card is not accepted, patients should ask for a pharmacist override or call the program's dedicated pharmacy help line, as processor rejection at the point of sale is often a keying error rather than a true exclusion.

Is Compounded Empagliflozin Legal in Iowa?

Compounded empagliflozin from a state-licensed 503A pharmacy is legal in Iowa as of 2026. Iowa's Board of Pharmacy regulates 503A compounding pharmacies under standards aligned with federal USP Chapter 795 guidelines [9].

503A pharmacies compound medications on a patient-specific, prescription-by-prescription basis. That is different from 503B outsourcing facilities, which can produce larger batches. A licensed Iowa 503A pharmacy can legally prepare empagliflozin capsules or tablets for an individual patient who has a valid prescription from a licensed prescriber.

The FDA has not designated empagliflozin as a drug in shortage, and it has not been placed on the FDA 503A bulks list (drugs that 503A pharmacies may compound without a specific shortage rationale) [10]. This matters because the legal basis for compounding a commercially available drug like empagliflozin depends on patient-specific clinical need documented in the prescription. Prescribers who direct patients to a 503A compounding pharmacy should document the clinical rationale in the chart, such as documented intolerance to an inactive ingredient in the branded tablet.

Compounded empagliflozin costs vary by pharmacy. Some Iowa 503A pharmacies affiliated with telehealth platforms offer compounded empagliflozin at substantially lower prices than the branded Jardiance list price. The trade-off is that compounded preparations have not undergone the same FDA manufacturing oversight as branded Jardiance, and bioavailability data for specific compounded formulations may not exist.

The HealthRX clinical team uses a four-question framework when evaluating whether a patient is an appropriate candidate for compounded empagliflozin in place of branded Jardiance:

1. Is the patient unable to obtain branded Jardiance at an affordable out-of-pocket cost after exhausting savings card and PAP options?
2. Does the prescribing physician have a documented clinical rationale for the compounded preparation?
3. Is the compounding pharmacy a licensed Iowa 503A facility with a valid DEA and state pharmacy board registration?
4. Will the patient's therapeutic response be monitored with the same frequency (HbA1c every 3 months until stable, then every 6 months; annual urine albumin-creatinine ratio) as they would receive on branded Jardiance?

If the answer to all four questions is yes, compounded empagliflozin may be a clinically appropriate and cost-effective option for that individual patient.

What Is the Clinical Evidence Behind Empagliflozin?

The evidence base for empagliflozin is one of the most scrutinized in modern cardiometabolic medicine. Three large outcome trials form the foundation.

EMPA-REG OUTCOME (N=7,020) enrolled patients with type 2 diabetes and established cardiovascular disease. Empagliflozin 10 mg or 25 mg daily versus placebo over a median of 3.1 years showed a 38% relative risk reduction in cardiovascular death (HR 0.62 to 95% CI 0.49, 0.77, P<0.001 for superiority), a 35% reduction in hospitalization for heart failure, and a 32% reduction in progression of kidney disease [1]. The New England Journal of Medicine published these results in 2015, and they prompted a landmark label expansion for the drug.

EMPEROR-Reduced (N=3,730) enrolled patients with heart failure with reduced ejection fraction (HFrEF), including those without diabetes. Empagliflozin 10 mg daily reduced the primary composite of cardiovascular death or hospitalization for heart failure by 25% relative to placebo (HR 0.75 to 95% CI 0.65, 0.86, P<0.001) [2]. This trial directly supported the FDA approval of Jardiance for HFrEF.

EMPA-KIDNEY (N=6,609) enrolled patients with CKD at risk of progression, with or without diabetes. Empagliflozin 10 mg daily reduced the risk of kidney disease progression or cardiovascular death by 28% relative to placebo (HR 0.72 to 95% CI 0.64, 0.82, P<0.001) [11]. The trial was stopped early by the independent data safety monitoring board due to clear efficacy. These results extended the evidence base for empagliflozin into CKD patients whose eGFR is as low as 20 mL/min/1.73 m2.

The 2024 ADA Standards of Care, Section 10 on Cardiovascular Disease and Risk Management, state: "For patients with type 2 diabetes and established cardiovascular disease, or at high cardiovascular risk, an SGLT2 inhibitor with demonstrated cardiovascular benefit should be considered regardless of baseline HbA1c or individualized HbA1c target" [5]. Iowa clinicians prescribing empagliflozin for cardiovascular risk reduction rather than glycemic control alone are operating within this guideline's explicit recommendation.

The American Heart Association's 2022 Guideline for the Diagnosis and Management of Heart Failure gives SGLT2 inhibitors a Class I recommendation (Level of Evidence: A) in patients with HFrEF, regardless of diabetes status [12]. That is the same evidence tier as ACE inhibitors and beta-blockers in HFrEF, reflecting the strength of the EMPEROR-Reduced data.

What Are the Side Effects and Monitoring Requirements for Empagliflozin?

Empagliflozin is generally well tolerated, but specific adverse effects require monitoring. The most common side effects are genital mycotic infections, affecting approximately 9.9% of women and 3.1% of men in clinical trial populations [13]. These are typically managed with standard antifungal treatment and improved perineal hygiene, and they rarely require drug discontinuation.

Diabetic ketoacidosis (DKA) is a rare but serious risk. The FDA issued a warning in 2015 after case reports of euglycemic DKA in patients taking SGLT2 inhibitors, including empagliflozin [10]. Euglycemic DKA is particularly dangerous because blood glucose may be only mildly elevated, delaying diagnosis. Patients scheduled for major surgery should hold empagliflozin at least 3 days before the procedure per most institutional protocols, and patients fasting for any reason should be counseled to withhold the drug.

Fournier's gangrene (necrotizing fasciitis of the perineum) is an extremely rare but life-threatening event associated with the entire SGLT2 inhibitor class. The FDA updated labels for all SGLT2 inhibitors in 2018 after reviewing 12 postmarketing cases over a 5-year period [10].

Lower limb amputation was associated with canagliflozin in the CANVAS trial but has not been reproduced for empagliflozin in EMPA-REG OUTCOME or subsequent analysis [14]. Current FDA labeling for Jardiance does not carry a black box warning for amputation, unlike canagliflozin.

Monitoring for Iowa patients on empagliflozin should include renal function (serum creatinine and eGFR) at baseline and at least annually, HbA1c every 3 months until stable then every 6 months, and urine albumin-creatinine ratio annually. Empagliflozin is not recommended for initiation in patients with eGFR <20 mL/min/1.73 m2 for glycemic indications, though the EMPA-KIDNEY trial data suggest some benefit may persist at lower eGFR ranges for renal protection [11].

Can I Get a Jardiance Prescription via Telehealth in Iowa?

Telehealth prescribing of empagliflozin is legal in Iowa in 2026. Iowa law permits synchronous audio-video telemedicine visits as a valid basis for prescribing, provided a prescriber-patient relationship is established and the standard of care for evaluation is met [15].

For empagliflozin, a telehealth prescriber should review at minimum: baseline eGFR, recent HbA1c, current medication list (for drug interactions, particularly with diuretics and insulin secretagogues), and cardiovascular or CKD history. A physical exam is not strictly required to establish a telehealth prescription for empagliflozin, unlike controlled substances that require in-person evaluation under the Ryan Haight Act.

Iowa does not require an in-person visit before a telehealth prescriber can send an empagliflozin prescription to an Iowa pharmacy. The prescription must come from a clinician licensed in Iowa or holding a valid Iowa telemedicine practice registration. HealthRX clinicians are licensed in Iowa and can evaluate patients for empagliflozin eligibility through a standard video or async intake visit.

After the telehealth evaluation, the prescription can be sent electronically to any Iowa retail pharmacy or to a licensed Iowa 503A compounding pharmacy if the clinician determines a compounded formulation is clinically appropriate.

What Are Iowa-Specific Patient Assistance Options?

Beyond the savings card, Boehringer Ingelheim operates a Patient Assistance Program (PAP) for uninsured or underinsured patients who meet income eligibility criteria [8]. Applications are submitted through the Boehringer Ingelheim Cares Foundation. Income thresholds shift annually, but the program has historically covered patients at or below 400% of the federal poverty level without other prescription coverage.

NeedyMeds.org and RxAssist.org both maintain current Iowa-specific program listings for Jardiance PAP enrollment. Iowa patients should have their prescribing clinician's office complete the enrollment paperwork, as most PAP applications require a physician signature and income documentation.

The Iowa Prescription Drug Corporation (IPDC) is a state-level discount program, though its discounts on branded specialty drugs like Jardiance are modest compared with the manufacturer PAP. Iowa patients with incomes above PAP thresholds but without commercial insurance may find more savings through the Jardiance.com savings card paired with a GoodRx price comparison across Des Moines, Cedar Rapids, Davenport, and Sioux City pharmacies.

State-funded Extra Help (Low Income Subsidy) for Medicare Part D can substantially reduce Jardiance cost for qualifying Iowa Medicare beneficiaries. The Social Security Administration administers Extra Help eligibility. In 2026, full Extra Help subsidy eliminates the deductible and reduces cost-sharing to a few dollars per prescription, which could make Jardiance accessible at near-zero out-of-pocket cost for low-income Iowa seniors who happen to be on a Part D plan that covers it [7].